Alnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to “Buy” Rating by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

Several other research analysts have also recently weighed in on ALNY. Truist Financial cut their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. HC Wainwright dropped their target price on shares of Alnylam Pharmaceuticals from $570.00 to $510.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Needham & Company LLC reduced their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday. Finally, Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research report on Tuesday, January 20th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $477.38.

Alnylam Pharmaceuticals Trading Up 1.9%

Shares of Alnylam Pharmaceuticals stock opened at $314.40 on Friday. The company has a market capitalization of $41.54 billion, a P/E ratio of 183.86 and a beta of 0.35. The stock has a fifty day simple moving average of $374.98 and a 200 day simple moving average of $424.03. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 119.85%. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.65) earnings per share. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,510 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70. Following the transaction, the executive vice president owned 29,728 shares of the company’s stock, valued at $10,787,399.36. This represents a 4.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the transaction, the executive vice president owned 21,264 shares of the company’s stock, valued at $9,615,155.52. The trade was a 36.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 31,305 shares of company stock valued at $12,459,785 in the last quarter. 1.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $29,000. HM Payson & Co. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $27,000. Finally, Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $32,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Amvuttra is powering large revenue gains and Alnylam reported full-year product revenues near $3B with strong year‑over‑year growth; the company also reported profitability for the first time — a clear fundamental positive for long‑term earnings potential. Business Wire: Alnylam Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Catalyst from analyst support — some firms (e.g., TD Cowen) are maintaining Buy ratings and framing Amvuttra as the catalyst for a longer‑term profitability inflection. TipRanks: Amvuttra-Driven Profitability Inflection Supports Buy Rating
• Neutral Sentiment: FY‑2026 revenue guidance was updated to roughly $5.3–$5.8B (slightly wide band vs. consensus), leaving mixed readthroughs for near‑term estimates and valuation models. Business Wire: FY‑2026 Guidance
• Neutral Sentiment: Analysts have trimmed price targets (e.g., Chardan, Needham) but many kept Buy ratings — this tempers upside expectations while still signaling continued institutional conviction. Benzinga: Analyst Price Target Changes
• Negative Sentiment: Market reaction to the Q4 release was mixed: some outlets flagged EPS and revenue misses vs. specific consensus numbers while others reported an EPS beat — the inconsistent takeaways have created volatility and investor uncertainty. Zacks: Q4 Earnings Beat, Sales Miss MarketBeat: Q4 Snapshot
• Negative Sentiment: Management signaled higher long‑term R&D/spend to fund pipeline ambitions and flagged execution/scaling risks for global Amvuttra rollout — comments that prompted some investors to downgrade longer‑term profit expectations. Seeking Alpha: Investors Revise Future Profit Expectations TipRanks: Execution Risks Loom
• Neutral Sentiment: Reported short‑interest figures in the feeds are effectively zero/placeholder and not informative for current positioning — ignore as a market signal until clearer data is posted.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.